Atara Biotherapeutics Appoints Brian Cherry to Board and Announces 2026 Annual Meeting Results

On June 11, 2026, Atara Biotherapeutics, Inc. appointed Brian Cherry to its Board of Directors as a Class I director and a member of the Audit Committee. Mr. Cherry will receive an initial equity award of 24,000 restricted stock units vesting over three years and an annual cash retainer of $55,000. Additionally, the company reported the results of its 2026 Annual Meeting of Stockholders held on June 9, 2026. Stockholders elected AnhCo Nguyen, Ph.D., and Nachi Subramanian to the Board to serve until 2029. Other approved proposals included an advisory vote on executive compensation, an amendment to the 2024 Equity Incentive Plan to increase the authorized shares by 400,000, and the ratification of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2026. Atara Biotherapeutics is a cellular therapy company specializing in T-cell immunotherapies.